These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 15325474

  • 21. Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs.
    Duncker DJ, Verdouw PD.
    Scand Cardiovasc J; 2002 May; 36(3):131-5. PubMed ID: 12079634
    [No Abstract] [Full Text] [Related]

  • 22. Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure.
    Kubo SH.
    Cardiology; 1997 May; 88 Suppl 2():21-7. PubMed ID: 9142432
    [Abstract] [Full Text] [Related]

  • 23. [Inotropic agents in advanced and refractory heart failure].
    Mangiavacchi M, Gronda E.
    Ital Heart J Suppl; 2003 Jan; 4(1):3-7. PubMed ID: 12690928
    [No Abstract] [Full Text] [Related]

  • 24. Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study.
    Schober KE, Rush JE, Luis Fuentes V, Glaus T, Summerfield NJ, Wright K, Lehmkuhl L, Wess G, Sayer MP, Loureiro J, MacGregor J, Mohren N.
    J Vet Intern Med; 2021 Mar; 35(2):789-800. PubMed ID: 33543810
    [Abstract] [Full Text] [Related]

  • 25. Beta-blockade in the management of systolic dysfunction.
    Abbott JA.
    Vet Clin North Am Small Anim Pract; 2004 Sep; 34(5):1157-70. PubMed ID: 15325475
    [Abstract] [Full Text] [Related]

  • 26. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P.
    J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
    [Abstract] [Full Text] [Related]

  • 27. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.
    Lombard CW, Jöns O, Bussadori CM.
    J Am Anim Hosp Assoc; 2006 Nov; 42(4):249-61. PubMed ID: 16822763
    [Abstract] [Full Text] [Related]

  • 28. Rationale and design of the enoximone clinical trials program.
    Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, Gerber MJ, Liard JF, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, Demets DL, Bristow MR.
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [Abstract] [Full Text] [Related]

  • 29. Will calcium sensitizers play a role in the treatment of heart failure?
    Nielsen-Kudsk JE, Aldershvile J.
    J Cardiovasc Pharmacol; 1995 Dec; 26 Suppl 1():S77-84. PubMed ID: 8907135
    [Abstract] [Full Text] [Related]

  • 30. Pharmacotherapy of congestive heart failure: pimobendan, a new approach to inotropic stimulation. Proceedings of a satellite symposium to the Xth European Congress of Cardiology. Vienna, Austria, August 31, 1988.
    J Cardiovasc Pharmacol; 1989 Dec; 14 Suppl 2():S1-64. PubMed ID: 2478785
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure.
    Hamabe L, Kawamura K, Kim SM, Yoshiyuki R, Fukayama T, Shimizu M, Fukushima R, Tanaka R.
    J Pharmacol Sci; 2014 Dec; 124(3):386-93. PubMed ID: 24599141
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
    Mizuno M, Yamano S, Chimura S, Hirakawa A, Takusagawa Y, Sawada T, Maetani S, Takahashi A, Mizuno T, Harada K, Shinoda A, Uchida S, Takeuchi J, Mizukoshi T, Endo M, Uechi M.
    J Vet Med Sci; 2017 Jan 20; 79(1):29-34. PubMed ID: 27644192
    [Abstract] [Full Text] [Related]

  • 37. Improvement of cardiac performance by pimobendan, a new cardiotonic drug, in the experimental failing dog heart.
    Satoh K, Satoh Y, Imagawa J, Taira N.
    Jpn Heart J; 1993 Mar 20; 34(2):213-9. PubMed ID: 8315818
    [Abstract] [Full Text] [Related]

  • 38. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy.
    Fuentes VL, Corcoran B, French A, Schober KE, Kleemann R, Justus C.
    J Vet Intern Med; 2002 Mar 20; 16(3):255-61. PubMed ID: 12041654
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.